About Us

Archives






Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Posted: August 29, 2021 at 1:49 am


WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the “Court”) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation, Lead Case No. 1:19-cv-10641-LJL (the “Consolidated Derivative Action”).

More here:
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.